Background-The Women's Healthy Lifestyle Project Clinical Trial tested the hypothesis that reducing saturated fat and cholesterol consumption and preventing weight gain by decreased caloric and fat intake and increased physical activity would prevent the rise in LDL cholesterol and weight gain in women during perimenopause to postmenopause. Methods and Results-There were 275 premenopausal women randomized into the assessment only group and 260 women into the intervention group. The mean age of participants at baseline was 47 years, and 92% of the women were white. The mean LDL cholesterol was 115 mg/dL at baseline, and mean body mass index was 25 kg/m 2 . The follow-up through 54 months was excellent. By 54 months, 35% of the women had become postmenopausal. At the 54-month examination, there was a 3.5-mg/dL increase in LDL cholesterol in the intervention group and an 8.9-mg/dL increase in the assessment-only group (Pϭ0.009). Weight decreased 0.2 lb in the intervention and increased 5.2 lb in the assessment-only group (Pϭ0.000). Triglycerides and glucose also increased significantly more in the assessment-only group than in the intervention group. Waist circumference decreased 2.9 cm in the intervention compared with 0.5 cm in the assessment-only group (Pϭ0.000). Conclusions-The trial was successful in reducing the rise in LDL cholesterol during perimenopause to postmenopause but could not completely eliminate the rise in LDL cholesterol. The trial was also successful in preventing the increase in weight from premenopause to perimenopause to postmenopause. The difference in LDL cholesterol between the assessment and intervention groups was most pronounced among postmenopausal women and occurred among hormone users and nonusers. (Circulation. 2001;103:32-37.) 
D uring the perimenopausal to postmenopausal years, women experience a substantial increase in their LDL cholesterol and total cholesterol and a small decrease in total HDL cholesterol. 1 They gain an average of about 1 lb per year and increase their waist circumference. 2 There are a decrease in bone mineral density and muscle mass and an increase in percent body fat even among women with no increase in total body weight. 3 The Women's Healthy Lifestyle Project (WHLP), a randomized clinical trial, tested the hypothesis that reducing consumption of saturated fat and cholesterol in their diet and preventing weight gain by decreasing both total and fat calories and moderately increasing physical activity among "healthy" women would prevent the rise in LDL cholesterol and weight gain from premenopause to perimenopause to postmenopause. This study tested an overall intervention and its effects on the risk factors, not the specific components on the risk factors (ie, the intervention to lower saturated fat and cholesterol versus weight gain prevention). This report focuses on change in LDL cholesterol levels.
The increase in total or LDL cholesterol during perimenopause to postmenopause has been noted in practically all populations, including those that have relatively low LDL cholesterol levels before menopause and consume very low levels of saturated fat and cholesterol in their diets. There is also a direct relationship between weight gain from perimenopause to postmenopause and rise in LDL cholesterol. 4, 5 The LDL cholesterol level in women, as well as in men, is reduced by a diet low in saturated fat and cholesterol. 6 These changes in LDL cholesterol are similar for men and women and are consistent with the Keys or Hegstead equations for the effects of various dietary saturated fat, polyunsaturated fat, and LDL cholesterol levels. 7 These dietary changes produce a greater decline in HDL cholesterol levels among women compared with men. 6 In addition to diet, estrogen therapy reduces LDL cholesterol levels. 8
Methods
Descriptions of recruitment and eligibility criteria have been previously published. 9, 10 Women were between 44 to 50 years of age and were sampled from voter registration lists in Allegheny County, Pennsylvania, between 1992 and 1994. 9, 10 Women with a prior hysterectomy and those on hormone replacement therapy (HRT) were excluded from the trial.
Study Design and Procedures
Participants completed a telephone interview, a screening visit, and a baseline visit to determine eligibility. The study protocol was approved yearly by the Institutional Review Board at the University of Pittsburgh. Written informed consent was obtained at the screening visit. All participants were provided with a health education pamphlet on reducing cardiovascular risk factors at baseline. Participants who reported smoking were advised to quit. Participants were randomly assigned to an assessment-only control group or to a lifestyle intervention group. Both groups attended follow-up clinic assessments at 6, 18, 30, 42, and 54 months after randomization.
Lifestyle Intervention
The lifestyle intervention was a 5-year cognitive-behavioral program aimed at preventing the increase in LDL cholesterol levels, preventing weight gain, and increasing leisure-time physical activity. 9, 10 Participants were asked to lower their dietary fat intake to 25% of daily calories, lower their saturated fat intake to 7% of calories, and lower their dietary cholesterol to 100 mg daily. All women were given a modest weight loss goal of 5 to 15 lb, depending on baseline weight status, and they were asked to reduce daily caloric intake to 1300 kcal until the weight goal was achieved. A lifestyle approach to increasing physical activity to 1000 to 1500 kcal expended weekly was used to facilitate weight control. The specific aims were to prevent rise in LDL cholesterol and weight among women with "average" levels of risk factors. The intervention included an intensive group program during the first 6 months and follow-up individual/group sessions from 6 through 54 months. 9
Statistical Methods
Descriptive statistics were used to describe baseline and sociodemographic variables. We used t tests and ANOVA to test the differences between intervention and control groups on risk factors. The primary end points of the trial were difference in the change in LDL cholesterol and weight between intervention and assessment-only groups at the end of the trial (54 months).
Results
There were 275 women randomly assigned to the assessment only group and 260 in the lifestyle intervention group. The mean age of the participants was 47Ϯ1.6 years (Table 1) . Table 1 summarizes selected baseline characteristics for the lifestyle intervention and control groups. No significant differences were found between groups on any of the variables.
The mean baseline LDL cholesterol was 116 mg/dL for the assessment group and 115 mg/dL for the intervention group. Mean baseline body mass index (BMI) was 25 kg/m 2 for both the assessment and intervention groups; 92% of the participants were white; 49% had 0 to 4 years of college; and 36% had more than a college education. Attendance at the 5 clinic follow-up assessments averaged 93%; 95% returned for the 54-month assessment. There was 1 death resulting from an accident.
There was an Ϸ10-mg/dL between-group difference in LDL cholesterol at 6 months and an Ϸ5.4-mg/dL betweengroup difference at 54 months (Table 2 and Figure 1 ). LDL cholesterol increased over time from the 6-month visit for both the intervention and assessment groups ( Table 2 ). The comparison of the change in LDL cholesterol between the intervention and control group was statistically significant at each time point in this study ( Table 2) .
We also assessed the categorical distributions of LDL cholesterol at the 54-month visit. Twenty-seven percent of the intervention group compared with only 16% of the assessment-only group had LDL cholesterol levels Ͻ100 mg/dL, whereas 40% of the assessment-only group and only 32% of the intervention group had LDL cholesterol levels Ͼ130 mg/dL (Pϭ0.007, Mantel-Haenszel test for linear comparison between the assessment and intervention groups).
We classified women as premenopausal, perimenopausal, or postmenopausal for analysis. At the 54-month follow-up, 56% of the participants in both the intervention and control groups were still menstruating regularly and were considered to be premenopausal; 10% were perimenopausal, having missed 3 to 11 consecutive periods; and 35% were postmenopausal, having missed 12 consecutive periods or having had a hysterectomy. There were 27 women who had a hysterectomy (13 in the intervention group and 14 in the assessment-only group), and 25 of the 27 also reported an oophorectomy. The difference in LDL cholesterol at the 54-month examination between the assessment and intervention groups was greater for the women who had become postmenopausal (8.7 versus 4.0 mg/dL for women who had remained premenopausal; Table 3 ). The statistical test for interaction of change in LDL cholesterol effect by menopausal status and treatment group, however, was not significant. Use of HRT was not affected by study intervention groups. At the 54-month examination, 30% (80 of 263) in the assessment group and 32% (79 of 245) in the intervention group were on HRT ( Table 4 ). A high percentage of women who had become postmenopausal (56% of control subjects, 61% of intervention) were on HRT. Many of the women were started on HRT before 12 months of amenorrhea and remained amenorrheic on HRT (almost always a combination of estrogen and continuous progesterone [medroxyprogesterone]). After 12 months of amenorrhea, the women were classified as postmenopausal, although it is likely that some were still premenopausal at the end of 12 months of HRT. Among the 159 women on HRT at the 54-month visit, 20 (13%) were on estrogen only, 127 (80%) were on estrogen and progesterone, 2 (1%) were on progesterone only, and 10 (6%) were on other therapies.
Hormone users had a smaller increase in LDL cholesterol, as expected for both the assessment and intervention groups. The difference between the assessment and intervention groups was similar (ie, 4.9 and 5.3 mg/dL for hormone uses and nonusers, respectively; Table 5 ). There was an Ϸ14mg/dL difference in LDL cholesterol between the assessment group not on HRT and the intervention group also on hormone therapy. There was no significant interaction between treatment group and use of HRT and changes in LDL cholesterol and other coronary heart disease risk factors.
There was a substantial increase in other risk factor levels to 54 months in the assessment versus intervention group (Table 2) . Triglycerides increased 18 mg/dL in the intervention and 30 mg/dL in the assessment-only group (PϽ0.01). Increases in triglycerides were similar among hormone users and nonusers (Table 5 ). There was a greater increase in triglycerides in the women who became menopausal for both the intervention and assessment-only groups ( Table 3) . HDL cholesterol levels (Table 2 ) decreased at 6 months in the intervention group, with little change in the assessment group. At 54 months, there was an increase in both the assessment and intervention groups (PϭNS). The increase in HDL cholesterol levels was limited to women on HRT for both the assessment and intervention groups ( Table 5) . Changes in apoB, apoA-1, and apoA-2 parallel the changes in LDL cholesterol, triglycerides, and HDL cholesterol. There was a significant decline in apoB for the intervention versus assessment-only group of 6.7 mg/dL at 6 months, 4.5-mg/dL difference at 18 months, and 4.6-mg/dL difference at 54 months ( Table 2) .
There was an increase in blood glucose levels for both the intervention and assessment-only groups, but the increase was significantly greater for the assessment-only compared with intervention group. At 54 months (Table 2) , fasting blood glucose had increased 3.3 mg/dL in the assessment compared with 1.6 mg/dL in the intervention group (PϽ0.05). At 6 months, systolic blood pressure was 3.5 mm Hg and diastolic blood pressure was 2.2 mm Hg lower (PϽ0.01) in the intervention compared with assessment-only group. The statistical significant differences in blood pressure, however, had disappeared by 54 months ( Table 2) . At 54 months, 15 women (9 in the assessment-only group, 6 in the intervention group) reported that they were being treated with drugs for hypertension. Seven other women (5 in the assessment group, 2 in the intervention group) reported use of diuretics.
Blood insulin levels were measured in 2 laboratories over the time of the study, so it was impossible to compare the change from baseline. Baseline insulin levels were the same in both groups. At both 6 and 54 months, the blood insulin levels were significantly lower in the intervention compared with the assessment group (13.5 versus 11.6 mmol/mL at 6 months and 11.3 versus 10.5 mmol/mL at 54 months). Very few women smoked cigarettes at baseline, Ϸ9% in both groups and Ϸ8% in both groups at 54 months (not shown).
There was about a 5.2-lb weight gain in the assessment group, consistent with our previous observation of about 1 lb per year, and a 1-lb decrease in weight in the intervention group (Table 2 and Figure 2 ). The significant decrease in waist circumference is consistent with weight change. At baseline, the intervention and comparison groups were both consuming about 11.5% to 11.8% saturated fat of total calories. At 6 months, the saturated fat intake had dropped to 7.9% in the intervention and 11.2% in the control group; at 54 months, it dropped to 9% in the intervention and 10.9% in the assessment group (Table 6 ). Total fat intake was Ϸ32% in both the assessment and intervention groups and dropped at 54 months to 30.4% in the assessment-only and 25.6% in the intervention group (Table 6 ). Oleic acid, monounsaturated fat, and dietary linoleic acid as measures of polyunsaturates decreased significantly more at 54 months in the intervention group compared with the assessment group, consistent with efforts to reduce the total fat intake. No attempt was made to increase omega-3 fatty acids, except to substitute fish for meat in the diet to reduce saturated fat consumption.
Total dietary cholesterol was 196 mg/d at baseline in both the assessment and intervention groups, increased to 212 mg/d in the control subjects, and declined to 154 mg/d in the intervention group (Pϭ0.000). There was no significant change in either dietary protein or carbohydrate consumption as percent of total calories (Table 6) . At 54 months, there was a positive correlation between change in weight (R 2 ϭ0.31, Pϭ0.000) and change in LDL cholesterol within the intervention group and a significant association between change in LDL cholesterol and the percent decrease in saturated fat (R 2 ϭ0.19, Pϭ0.002). Furthermore, there was a strong correlation between change in weight and reported change in saturated fat (R 2 ϭ0.19, Pϭ0.002; not shown).
Discussion
The WHLP clinical trial has demonstrated that a lifestyle intervention that combines dietary changes, a reduction in calories and total fat calories, and a decrease in both saturated fat and dietary cholesterol, along with increasing leisure time physical activity, resulted in a significantly smaller increase in LDL cholesterol levels over 54 months in the intervention compared with the assessment group. There were also significant differences in triglycerides, systolic and diastolic blood pressures, blood glucose, and insulin for the intervention compared with assessment-only group. Differences in weight gain were also maintained over the 54 months of the trial.
The rise in LDL cholesterol during perimenopause to postmenopause was blunted in the intervention group but not totally prevented, as was hoped in the original hypothesis. Still, the 8.7-mg/dL difference between groups (Ϸ7% from baseline levels) among menopausal women is impressive.
We have previously shown in the Healthy Women Study that LDL cholesterol levels measured during premenopause to perimenopause were significant predictors of coronary and aortic calcification as measured by electron beam CT among women mean who were 61 years of age, Ϸ8 to 10 years postmenopausal. The relationship between LDL cholesterol and coronary and aortic calcification was linear from a relatively low level of LDL cholesterol, probably Ϸ100 to 120 mg/dL. 11 The very high percentage of women on HRT (31%) as they became menopausal affects some of the analysis of the 54-month data. The women in the study were generally well educated, and none had a prior hysterectomy or oophorectomy or history of coronary heart disease or diabetes. No information was provided by the study staff to encourage or discourage use of HRT. Questions regarding the use of HRT were referred back to the women's primary care or speciality physicians. Women were often placed on HRT before cessation of menses.
We originally hypothesized that the intervention group would be more likely to develop menopausal symptoms such as hot flashes because of their weight loss or failure to gain weight during perimenopause to postmenopause and would be much more likely to use HRT. In the Healthy Women Study, as well as in other studies, there is a strong inverse relationship between BMI and likelihood of use of HRT. The prevalence of symptoms (not shown) and use of HRT (Table  4) were similar for the intervention and assessment groups. Thus, it does not appear that the intervention, in spite of the prevention of weight gain, resulted in greater use of HRT to manage symptoms. We have, however, previously published data showing that there was greater bone loss in the intervention group compared with the assessment group at 18 months and that the degree of bone loss was related to the amount of weight loss. 12 There were also higher levels of markers of bone loss in the intervention compared with the assessment group at 18 months. 12 The trial was not designed, as noted, to determine the efficacy of specific intervention components: prevention of weight gain through caloric reduction, low fat diet, and increased physical activity compared with fatty acid composition (ie, decreased saturated fat and cholesterol in the diet).
Clearly, the intervention is labor intensive. Prevention of weight gain and a rise in LDL cholesterol could have a major impact in reducing cardiovascular morbidity and mortality among women. [13] [14] [15] Newer nutritional approaches became available since the beginning of the trial that may further enhance the reduction of LDL cholesterol levels. 16, 17 In conclusion, this trial has shown the efficacy of this intervention in preventing or reducing the rise in LDL cholesterol and weight, the 2 primary end points of the trial. 
